All In Biotech

Drug Trial Radar · NCT06967259

ENA-001 for Opioid Induced Respiratory Depression

A Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ENA-001 Administered as Intravenous (IV) and Intramuscular (IM) Doses

Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

62

Actual

Start

May 14, 2025

Primary completion

Aug 12, 2026

Study completion Aug 12, 2026

Sponsor

Lead sponsor
Enalare Therapeutics Inc.Industry
Sponsor type
Industry
Collaborators
National Institute on Drug Abuse (NIDA)
First posted
May 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a Phase I clinical trial to assess the safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) profiles with single intravenous (IV) and intramuscular (IM) doses of ENA-001.

Conditions

  • Respiratory Depression

Interventions

  • ENA-001Drug

    Concentration for ENA-001 IV formulation is 10 mg/mL. Concentration for ENA 001 IM formulation is 30 mg/mL.

  • Placebo ComparatorDrug

    Placebo comes in 5 mL/vial. Placebo matches ENA-001 injection; however, no ENA-001 is included.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Range values of laboratory tests (Safety)Time frame: From screening to follow up visit (approx. 8 weeks)
  2. Range values of special chemistry tests (Safety)Time frame: From screening to follow up visit (approx. 8 weeks)
  3. Vital Sign measurements (Safety and tolerability)Time frame: From screening to follow up visit (approx. 8 weeks)
  4. Measurement of ECG parameters (Safety and tolerability)Time frame: From screening to follow up visit (approx. 8 weeks)
  5. Complete Physical Exam Findings (Safety and tolerability)Time frame: From screening to follow up visit (approx. 8 weeks)
  6. Incidence of Adverse Events (Safety and tolerability)Time frame: From screening to follow up visit (approx. 8 weeks)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • South Florida Research Phase I-IV

    Miami, Florida

  • Dr. Vince Clinical Research

    Overland Park, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.